Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer

First Posted Date
2009-04-13
Last Posted Date
2017-05-02
Lead Sponsor
University of South Florida
Registration Number
NCT00880386

Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2009-04-13
Last Posted Date
2021-02-21
Lead Sponsor
University of South Florida
Target Recruit Count
20
Registration Number
NCT00879879
Locations
🇺🇸

University of Cincinnati, Cincinnati, Ohio, United States

Olmesartan Medoxomil Versus Losartan in Patients With Hypertension

First Posted Date
2009-03-06
Last Posted Date
2009-07-23
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
130
Registration Number
NCT00857285
Locations
🇨🇳

Kaohsiung Medical University Hospital, Kaohsiung, Taiwan

🇨🇳

National Taiwan University Hospital, Taipei, Taiwan

🇨🇳

Chung Shun Medical University Hospital, Taichung City, Taiwan

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

First Posted Date
2009-03-05
Last Posted Date
2010-09-29
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
287
Registration Number
NCT00856271

Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-10-31
Last Posted Date
2022-12-22
Lead Sponsor
University Hospital, Ghent
Target Recruit Count
22
Registration Number
NCT00782327
Locations
🇧🇪

University Hospital Ghent, Ghent, Belgium

Adiponectin and Insulin Resistance in Diabetic Nephropathy

Not Applicable
Completed
Conditions
First Posted Date
2008-10-17
Last Posted Date
2008-10-20
Lead Sponsor
Health Science Center of Xi'an Jiaotong University
Target Recruit Count
80
Registration Number
NCT00774904
Locations
🇨🇳

Shanghai No.3 people's hospital, Shanghai, China

Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2008-10-01
Last Posted Date
2015-11-04
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
303
Registration Number
NCT00763893
Locations
🇫🇷

Hôpital Bichat, Paris, France

Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)

Phase 3
Completed
Conditions
Interventions
First Posted Date
2008-09-22
Last Posted Date
2024-06-18
Lead Sponsor
Organon and Co
Target Recruit Count
101
Registration Number
NCT00756938

The Effect of Losartan Versus Amlodipine-based Therapy in Ischemic Stroke (0954-338)(COMPLETED)

Phase 4
Completed
Conditions
Interventions
First Posted Date
2008-09-18
Last Posted Date
2013-10-23
Lead Sponsor
Taipei Veterans General Hospital, Taiwan
Target Recruit Count
40
Registration Number
NCT00754429

Aliskiren's Effect on Arterial Stiffness and Platelet Function in Patients With Diabetes Mellitus (DM)

First Posted Date
2008-08-12
Last Posted Date
2008-08-12
Lead Sponsor
Assaf-Harofeh Medical Center
Target Recruit Count
40
Registration Number
NCT00732407
© Copyright 2024. All Rights Reserved by MedPath